「statistics」の検索結果

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.

日本語の概要は準備中です。原文の説明を表示しています。

Reads, validates, and prepares CDISC SDTM and ADaM clinical trial data for analysis. Covers SDTM domain joins (DM, AE, EX, VS, LB, DS), ADaM architecture (ADSL, BDS, OCCDS, ADTTE) with traceability, treatment-emergent AE conventions, baseline derivation, SUPPQUAL/NSV handling, Define-XML 2.1, and Pinnacle 21 / CORE validation. Use when working with clinical trial datasets in CDISC SDTM/ADaM format, preparing analysis-ready data, or validating for regulatory submission.

日本語の概要は準備中です。原文の説明を表示しています。

Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.

日本語の概要は準備中です。原文の説明を表示しています。

Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Implements missing-data sensitivity analyses for confirmatory clinical trials including MMRM under MAR (with Kenward-Roger correction), reference-based multiple imputation (J2R, CR, CIR, LMCF per Carpenter-Roger 2013), Permutt delta-adjustment / tipping-point analysis, pattern-mixture identifying restrictions (CCMV, NCMV, ACMV), and the Cro vs Bartlett variance debate. Use when handling missing primary or secondary endpoint data in regulatory submissions following NRC 2010 and ICH E9(R1).

日本語の概要は準備中です。原文の説明を表示しています。

Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.

日本語の概要は準備中です。原文の説明を表示しています。

Tests associations between categorical variables in clinical data using chi-square, Fisher's exact, Boschloo, Cochran-Mantel-Haenszel, and modern McNemar variants with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen). Use when analyzing categorical outcomes, paired binary endpoints, or testing treatment-outcome independence in confirmatory or exploratory clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Estimate bivariate genetic correlation (rg) between traits from GWAS summary statistics or individual-level genotypes using cross-trait LDSC, HDL, LAVA, rho-HESS, GREML-bivariate, Popcorn, and HDL-L. Use when quantifying shared genetic architecture between two traits, screening MR validity before causal inference, distinguishing global from locus-level rg, estimating trans-ancestry rg, separating partial from full causation via LCV gcp, or producing a STROBE-MR-compliant cross-trait sensitivity battery. Cross-trait LDSC intercept absorbs sample overlap and is NOT a bias; HDL is biased under sample overlap above ~5%. High rg between exposure and outcome motivates CHP-aware MR sensitivity (CAUSE, LHC-MR).

日本語の概要は準備中です。原文の説明を表示しています。

Estimate causal effects of an exposure on an outcome from GWAS summary statistics using genetic instruments. Implements IVW (fixed/random), MR-Egger, weighted median/mode, MR-RAPS, CAUSE, GSMR-HEIDI, MR-PRESSO, MVMR, MR-Clust, LCV, and LHC-MR via TwoSampleMR, MendelianRandomization, MR-PRESSO, cause, and lhcMR. Use when testing causal direction between traits, evaluating drug-target effects via cis-pQTL/cis-eQTL, performing multivariable mediation MR, distinguishing causation from correlated horizontal pleiotropy, or producing STROBE-MR-compliant sensitivity batteries.

日本語の概要は準備中です。原文の説明を表示しています。

Fits structural equation models to GWAS summary statistics using GenomicSEM (Grotzinger 2019), including common-factor models, confirmatory factor models, ESEM, common-factor GWAS with Q_SNP heterogeneity, multivariate Wald tests, and stratified GenomicSEM partitioned heritability. Reconciles results against MTAG multi-trait analysis. Handles sample overlap via the LDSC sampling-covariance matrix, identifies and resolves Heywood cases, and verifies model fit with CFI / RMSEA. Use when modeling latent genetic architecture across correlated traits, running multivariate GWAS on a shared factor, distinguishing factor-mediated from trait-specific SNP effects, or comparing GenomicSEM common-factor results against MTAG when both depend on accurate sampling covariance.

日本語の概要は準備中です。原文の説明を表示しています。

Test whether two or more traits share a causal variant at a locus using Bayesian colocalization (coloc.abf, coloc.susie, HyPrColoc, moloc, eCAVIAR, SMR/HEIDI, PWCoCo, SharePro). Use when integrating GWAS with eQTL/sQTL/pQTL/mQTL, distinguishing shared causal variants from LD-driven coincidence, handling allelic heterogeneity, choosing between single-causal vs multi-causal methods, picking PP.H4 thresholds, running sensitivity over p12, or harmonising summary statistics for colocalization.

日本語の概要は準備中です。原文の説明を表示しています。

The science of learning through controlled experimentation. A/B testing isn't about picking winners—it's about building a culture of validated learning and reducing the cost of being wrong. This skill covers experiment design, statistical rigor, feature flagging, analysis, and building experimentation into product development. The best experimenters know that every test, positive or negative, teaches something valuable. Use when "a/b test, experiment, hypothesis, statistical significance, sample size, feature flag, variant, control, treatment, p-value, conversion rate, test winner, split test, experimentation, testing, statistics, feature-flags, hypothesis, growth, optimization, learning, validation" mentioned.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill when the user uploads Excel (.xlsx/.xls) or CSV files and wants to perform data analysis, generate statistics, create summaries, pivot tables, SQL queries, or any form of structured data exploration. Supports multi-sheet Excel workbooks, aggregation, filtering, joins, and exporting results to CSV/JSON/Markdown.

日本語の概要は準備中です。原文の説明を表示しています。

Identifies outdated elements in provided content and suggests updates to maintain freshness. Finds statistics, dates, and examples that need updating. Use PROACTIVELY for older content.

日本語の概要は準備中です。原文の説明を表示しています。

Display project statistics — phases, plans, requirements, git metrics, and timeline

日本語の概要は準備中です。原文の説明を表示しています。

Analyze the threat landscape using MISP (Malware Information Sharing Platform) by querying event statistics, attribute distributions, threat actor galaxy clusters, and tag trends over time. Uses PyMISP to pull event data, compute IOC type breakdowns, identify top threat actors and malware families, and generate threat landscape reports with temporal trends.

日本語の概要は準備中です。原文の説明を表示しています。

Comprehensive dimension analysis and reporting for CJA. Use this skill whenever the user wants to analyze one or more dimensions — including cardinality, distribution/skew, trends, anomalies, data quality errors, comparisons, and forecasting. Also trigger when someone asks "what are the top values for...", "dimension health", "explore this dimension", "dimension dashboard", "dimension statistics", "data quality check on a dimension", "dimension cardinality", "dimension trends", "dimension skew", "dimension anomalies", "compare dimensions", or any similar request to understand what's inside a CJA dimension. Produces an interactive HTML dashboard or a markdown report. Works with the CJA MCP server.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a draft in Turkish, English, or both reads as AI-generated and needs revision that removes machine writing patterns and translation calques while preserving meaning, citations, statistics, and the author's voice.

日本語の概要は準備中です。原文の説明を表示しています。

Manage and monitor local Pi-hole instance. Query FTL database for statistics (blocked ads, top clients) and control service via CLI. Use when user asks "how many ads blocked", "pihole status", or "update gravity".

日本語の概要は準備中です。原文の説明を表示しています。

Analyze A/B test results for statistical significance with ship, extend, or kill recommendations

日本語の概要は準備中です。原文の説明を表示しています。

Rigorous benchmarking of multi-agent coordination systems: experiment design, statistical analysis, human evaluation protocols, and reproducible reporting. NOT FOR ML model evaluation (use llm-evaluation-harness), A/B testing for web products, survey design, or general data science.

日本語の概要は準備中です。原文の説明を表示しています。